Clinical experience with 0.05% halometasone/1% triclosan cream in the treatment of acute infected and infection-prone eczema in Egypt.
This is a report of a non-comparative trial to assess the usefulness of a 0.05% halometasone and 1% triclosan combination in a cream base in the treatment of acute infected and infection-prone eczematous skin disorders. The trial was carried out in three centres. Of the 126 patients admitted to the trial, 25 were lost to follow-up. The remaining 101 patients utilized the cream as the only treatment during the 3-week duration of therapy. Medication was applied to the lesions twice daily without occlusive dressing. The cream gave either excellent or good results in 89% of cases. Infection, which was initially present in 38 cases, disappeared within 5 days from 27 (71%) of them and within 6-10 days from a further six (16%) cases. The therapeutic effect was first noted (in 43 cases) within a mean of 2.7 days (+/- 1.01). The cream did not give rise to any serious local unwanted effects. Systemic unwanted effects were suspected in an 8-month old infant with extensive atopic dermatitis. The findings in this study substantiate those of other investigators that this halometasone/triclosan preparation combines potent and rapid therapeutic effect with excellent local and systemic tolerability.
Abdel Aal
H
H
Department of Dermatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Abdallah
M A
MA
Iskandar
I O
IO
Salama
N R
NR
D000208:Acute Disease; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004485:Eczema / Q000188:drug therapy* / Q000453:epidemiology; D004534:Egypt; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009824:Ointments; D010647:Phenyl Ethers / Q000008:administration & dosage*; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors; D014260:Triclosan / Q000008:administration & dosage* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D009824:Ointments; D010647:Phenyl Ethers; D014260:Triclosan; D001623:Betamethasone; C036518:halometasone